Advertisement


Giannis S. Mountzios, MD, on SCLC: Intracranial Effect of Tarlatamab vs Chemotherapy

ASCO 2026

Advertisement

Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).



Related Videos

Immunotherapy

Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden

Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580). 

Prostate Cancer

Atish Choudhury, MD, PhD: Can Patients With an Exceptional Response to ARPIs Interrupt ADT?

Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004). 

Gastrointestinal Cancer

Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer

Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).

Bladder Cancer

Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma

Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508). 

Lymphoma

Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care

Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling. 

Advertisement

Advertisement




Advertisement